HealthAsianet Newsable
Sellas Life Sciences Stock Rises Ahead of Phase 3 Data
in5points
Sellas Life Sciences stock rose premarket as the company nears a critical Phase 3 readout for acute myeloid leukemia (AML).
CEO Angelos Stergiou discussed on "FOX & Friends" that AI and precision medicine could accelerate drug development and improve patient selection.
The Phase 3 trial results are expected to be a key catalyst for the stock's performance.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically